Savolitinib

Savolitinib
Clinical data
Other names	Volitinib
Identifiers
	IUPAC name 3-[(1S)-1-Imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine;
CAS Number	1313725-88-0;
ChemSpider	34501055;
KEGG	D11139;
ECHA InfoCard	100.238.920
Chemical and physical data
Formula	C17H15N9
Molar mass	345.370 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H](C1=CN2C=CN=C2C=C1)N3C4=NC(=CN=C4N=N3)C5=CN(N=C5)C;
	InChI InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1; Key:XYDNMOZJKOGZLS-NSHDSACASA-N;

Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca.[1] It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma.[2]

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.